Furthermore, we are focusing on executing successful launches of both Monjuvi and Pemazyre, and we expect Tabrecta royalties to increase following the approvals and subsequent launches by Novartis in both the U.S. and Japan.
Refer to the input text as context and select the correct relationship between 'Tabrecta' and 'Novartis' from the available options.
Options: operator, owner of, location of formation, manufacturer